BD appoints Bilal Muhsin to lead new Connected Care segment

NEW YORK - BD (Becton, Dickinson and Company) (NYSE:BDX), a prominent $49.5 billion healthcare equipment company, has appointed Bilal Muhsin as executive vice president and president of its future Connected Care segment, effective July 2, the medical technology company announced Monday. According to InvestingPro data, BD maintains a strong market position with annual revenues of nearly $21 billion.

Muhsin will report to Chairman, CEO and President Tom Polen and serve on BD’s Executive Leadership Team. In this newly created role, he will lead the Connected Care segment, which aims to combine advanced analytics and AI solutions with the company’s smart devices to enhance patient care efficiency. This strategic move comes as BD shows strong financial health, with InvestingPro analysis indicating positive net income growth expectations for this year.

The appointment aligns with BD’s previously announced plans to update its structure as part of its New BD strategy. Muhsin will oversee the segment’s organizational capabilities, commercial strategy, innovation initiatives, and operational excellence. The company’s commitment to shareholder value is evident in its 54-year track record of consecutive dividend increases, as revealed by InvestingPro analysis, which offers comprehensive insights through its Pro Research Report covering 1,400+ top US stocks.

"Bilal will have a profound impact at BD as we advance our connected care strategy with cutting-edge, AI-driven technology that transforms patient care," Polen said in the press release.

Muhsin joins BD after 25 years at Masimo, a health technology manufacturer, where he most recently served as chief operating officer. His previous roles at Masimo included executive vice president of engineering, marketing and regulatory. He holds more than 50 patents in medical systems communication, analytics, and patient monitoring systems.

The new Connected Care segment will focus on areas including connected medication management, advanced workflow robotics, and smart monitoring solutions, according to the company statement.

Muhsin holds a Bachelor of Science degree in Computer Science from San Diego State University. BD maintains solid financial metrics with a gross profit margin of 46% and healthy cash flows, positioning the company well for its strategic initiatives in connected care technology.

In other recent news, Becton Dickinson has been the subject of multiple analyst evaluations and corporate developments. Stifel analysts reaffirmed their Buy rating for Becton Dickinson, maintaining a price target of $224. This decision followed a meeting with company executives, where Becton Dickinson’s management addressed mixed second-quarter results and provided a positive outlook despite macroeconomic challenges. Barclays analysts, however, lowered their price target for the company to $241, citing adjustments in sales and earnings estimates due to ongoing tariff impacts. Despite this, they maintained an Overweight rating, aligning their estimates with the company’s guidance.

Citi analysts downgraded Becton Dickinson from Buy to Neutral, reducing their price target to $185. They highlighted the complexity of predicting the company’s performance amidst its ongoing separation of the Biosciences unit. This strategic move is anticipated to be announced in the summer and is closely watched by investors for its potential impact on Becton Dickinson’s financial landscape. Meanwhile, Piper Sandler analysts noted Becton Dickinson among medtech stocks that have potential for better valuation multiples, though SOLV and ALGN were emphasized as top picks for value investments. These developments reflect a period of strategic transitions and varying analyst perspectives on Becton Dickinson’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.